Intercept Pharmaceuticals Inc Quick Ratio (ICPT) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Intercept Pharmaceuticals inc   (NASDAQ: ICPT)

Intercept Pharmaceuticals Inc 's Quick Ratio

ICPT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Intercept Pharmaceuticals Inc 's Cash & cash equivalent, this led to improvement in Intercept Pharmaceuticals Inc 's Quick Ratio to 1.13, Quick Ratio remained below Intercept Pharmaceuticals inc average.

Within Major Pharmaceutical Preparations industry 413 other companies have achieved higher Quick Ratio than Intercept Pharmaceuticals Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 1972, from total ranking in the second quarter 2023 at 2253.

Explain Quick Ratio?
How much Cash & cash equivalents ICPT´s has?
What are ICPT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ICPT Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -59 % 23.51 % 37.13 % 104.73 % 54.04 %
Y / Y Cash & cash equivalent Change -9.24 % 134.8 % 27.08 % -44.68 % -73.06 %
Quick Ratio MRQ 1.13 0.73 0.3 0.22 0.51
ICPT's Total Ranking # 1972 # 2253 # 2201 # 3576 # 2630
Seq. Current Liabilities Change -51.43 % -9.7 % -9.98 % 3.83 % 46.33 %
Seq. Cash & cash equivalent Change -24.59 % 121.86 % 21.55 % -55.37 % 95.1 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 414
Healthcare Sector # 757
Overall Market # 1972


Quick Ratio Statistics
High Average Low
30.79 8.3 0.22
(Jun 30 2015)   (Dec 31 2022)




Financial Statements
Intercept Pharmaceuticals Inc 's Current Liabilities $ 91 Millions Visit ICPT's Balance sheet
Intercept Pharmaceuticals Inc 's Cash & cash equivalent $ 103 Millions Visit ICPT's Balance sheet
Source of ICPT's Sales Visit ICPT's Sales by Geography


Cumulative Intercept Pharmaceuticals Inc 's Quick Ratio

ICPT's Quick Ratio for the trailling 12 Months

ICPT Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 12.36 % 51.39 % 46.63 % 37.68 % -18.98 %
Y / Y Cash & cash equivalent TTM Growth 12.88 % -41.51 % -70.94 % -79.8 % -80.96 %
Quick Ratio TTM 0.49 0.43 0.35 0.36 0.49
Total Ranking TTM # 4387 # 1757 # 4019 # 1208 # 3996
Seq. Current Liabilities TTM Growth -15.46 % 4.39 % 7.44 % 18.49 % 13.91 %
Seq. Cash & cash equivalent TTM Growth -2.89 % 27.62 % 4.85 % -13.13 % -49.68 %

Quick ratio ranking by company, industry and sector >> Back to ICPT Financial Strength Comparisons >> Go to Compare ICPT Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Intercept Pharmaceuticals Inc 's average Cash & cash equivalent, this led to increase in in Intercept Pharmaceuticals Inc 's Quick Ratio to 0.49, Quick Ratio remained below ICPT average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 553 other companies have achieved higher Quick Ratio than Intercept Pharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 1757 to 4387.

Explain Quick Ratio?
How much Cash & cash equivalents ICPT´s has?
What are ICPT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 554
Healthcare Sector # 1120
Within the Market # 4387


trailing twelve months Quick Ratio Statistics
High Average Low
23.16 6.09 0.35
(Sep 30 2015)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Hepion Pharmaceuticals Inc   3.07 $ 19.284  Millions$ 6.290  Millions
Edesa Biotech Inc   3.06 $ 5.400  Millions$ 1.762  Millions
Quoin Pharmaceuticals Ltd   3.05 $ 13.963  Millions$ 4.580  Millions
Azitra Inc   3.03 $ 4.400  Millions$ 1.454  Millions
Nextcure Inc   2.98 $ 19.519  Millions$ 6.552  Millions
Gain Therapeutics inc  2.93 $ 12.233  Millions$ 4.179  Millions
Corcept Therapeutics Inc  2.91 $ 355.225  Millions$ 121.873  Millions
Ainos Inc   2.89 $ 2.371  Millions$ 0.820  Millions
Xoma Royalty Corporation  2.86 $ 33.472  Millions$ 11.702  Millions
Tvardi Therapeutics Inc   2.81 $ 62.875  Millions$ 22.384  Millions
G1 Therapeutics Inc   2.80 $ 94.352  Millions$ 33.653  Millions
Aptevo Therapeutics Inc   2.80 $ 19.110  Millions$ 6.836  Millions
Monopar Therapeutics Inc   2.78 $ 5.515  Millions$ 1.982  Millions
Clene Inc   2.76 $ 42.113  Millions$ 15.268  Millions
Mersana Therapeutics inc   2.74 $ 186.283  Millions$ 67.933  Millions
Neubase Therapeutics inc   2.73 $ 12.696  Millions$ 4.650  Millions
Genprex Inc   2.70 $ 11.711  Millions$ 4.338  Millions
Evoke Pharma Inc   2.68 $ 5.965  Millions$ 2.227  Millions
Hookipa Pharma inc   2.65 $ 107.676  Millions$ 40.576  Millions
Bellicum Pharmaceuticals Inc   2.63 $ 5.909  Millions$ 2.249  Millions
Kiora Pharmaceuticals Inc   2.59 $ 5.400  Millions$ 2.082  Millions
Revelation Biosciences Inc   2.59 $ 13.995  Millions$ 5.400  Millions
Alaunos Therapeutics Inc   2.55 $ 11.944  Millions$ 4.676  Millions
23andme Holding Co  2.52 $ 256.386  Millions$ 101.601  Millions
Alnylam Pharmaceuticals Inc   2.52 $ 2,395.867  Millions$ 949.785  Millions
Pacira Biosciences inc   2.51 $ 235.188  Millions$ 93.661  Millions
Arrowhead Pharmaceuticals Inc   2.44 $ 292.735  Millions$ 119.992  Millions
Apellis Pharmaceuticals Inc   2.44 $ 452.414  Millions$ 185.630  Millions
Vyne Therapeutics Inc   2.40 $ 15.502  Millions$ 6.449  Millions
Beone Medicines Ltd   2.40 $ 3,078.884  Millions$ 1,283.297  Millions

Date modified: 2026-09-08T15:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.